Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Disc Medicine, Inc.

Get SEC filing alerts via email and in your feed for Disc Medicine, Inc.

IRON

Disc Medicine, Inc.

About Disc Medicine, Inc.

Disc Medicine, Inc. is a biopharmaceutical company focused on developing therapies for hematologic diseases. Its pipeline includes product candidates targeting red blood cell formation, heme biosynthesis, and iron homeostasis. The company leverages validated biological pathways to address conditions like porphyrias, anemia, and polycythemia vera, aiming to improve patient outcomes through innovative, mechanism-based treatments and strategic collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Disc Medicine, Inc.

1
1
Disc Medicine, Inc. Disc Medicine Reports Increased Losses and Rising Expenses in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Disc Medicine, Inc. Disc Medicine Reports $212.2 Million Net Loss and Progress on Clinical Trials in Annual Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Disc Medicine, Inc. Disc Medicine Reports $62.3 Million Net Loss in Q3 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Disc Medicine, Inc. Disc Medicine Reports $55.2 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Disc Medicine, Inc. Disc Medicine Reports $34.1 Million Net Loss in Q1 2025, Increases Cash Reserves to $694.7 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Disc Medicine, Inc. Disc Medicine Reports Significant Financial Developments, Net Loss of $26.6M in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments